Advances in Infectious Diseases, 2015, 5, 57-62
Published Online March 2015 in SciRes.
Morbidity and Mortality Weekly Report
Recommendations and Reports: July 7, 2006 / Vol. 55 / No. RR-9
Review Article: Journal of Nutritional Health & Food Science
Vitamin Deficiency and Tuberculosis: Need for Urgent Clinical Page 1- 6
Eur Respir J 2017; 50: 1700918
Research Article
BMC Infectious Diseases 2012, 12:262; doi:10.1186/1471-2334-12-262
This report presents an overview of the transition process in Azerbaijan, some sustainability aspects and challenges stemming from donor withdrawal from TB-related activities, along with recommendations on how to overcome transition-related difficu...lties and ensure sustainability.
more
The guidelines are aimed at clinical professionals directly involved with and responsible for the care of adults with HIV infection, and at community advocates responsible for promoting the best interests and care ... medbox">of HIV-positive adults. They should be read in conjunction with other published BHIVA guidelines.
The 2016 interim update to the 2015 BHIVA antiretroviral guidelines has been published online to include tenofovir-alafenamide/emtricitabine as a preferred NRTI backbone for first-line therapy. Changes were based on new data and the consensus opinion of the writing committee. All changes to the guideline are highlighted and include updates to the chronic kidney disease and bone disease sections of special populations and some small changes to managing virological failure.
The 2019 interim statement provides updated advice on treatment with two-drug regimens
more
Time has seen management for Cystic Fibrosis (CF) advance drastically, most recently in the development of the disease-modifying triple combination therapy ivacaftor/tezacaftor/elexacaftor. There is currently limited evidence regarding both the glob...al epidemiology of CF and access to this transformative therapy - and therefore where needs are not being met. Therefore, this study aims to define gaps in access to CF treatment. The results show that a significant CF patient burden exists in countries where disease-modifying drugs are unavailable, and final figures are likely underestimates. This analysis shows the potential to improve rates of diagnosis and treatment for CF, so a higher percentage of patients receive the most effective triple combination treatment.
more